Complications and Cardiovascular Mortality during COVID-19. Sudden Death Research Group (GIMS)

Luis Alberto Ochoa Montes

2020, Number 4

<< Back Next >>

Rev Acta Médica 2020; 21 (4)

Complications and Cardiovascular Mortality during COVID-19. Sudden Death Research Group (GIMS)

Ochoa MLA

Full text

How to cite this article

Language: Spanish
References: 9
Page: 1-5
PDF size: 127.92 Kb.

Text Extraction

No abstract.

REFERENCES

Phelan A.L., Katz R., Gostin L.O. The Novel Coronavirus Originating in Wuhan China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10.
WHO. WHO Director-General's opening remarks at the mission briefing on COVID-19-11 March 2020. 2020. [acceso: 16/10/2020]. Disponible en: https://www.who.int/ dg/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19-12-march-2020.
Am J Emerg Med. 2020; 38(7):1504–1507. [acceso: 16/10/2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165109/.
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;2019(1):25-8, [acceso: 16/1/2020]. Disponible en: http://dx.doi.org/10.1001/ jama.2020.2648.
Driggin E, Madhavan M V, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020;75(18):2352 LP-2371. [acceso: 16/10/2020]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC7198856/.
Giudicessi J, Noseworthy P, Friedman P, Ackerman M. Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19. Mayo Clin Proc. 2020;95(1):1-20.
Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):1-10. [acceso: 16/10/2020]. Disponible en: https://doi.org/10.1186/s40779-020-00240-0.
Paz Ocaranza M, Riquelme JA, García L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. NatRevCardiol. 2020;17(2):116-29, [acceso: 16/10/2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31427727/.
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):1-7. [acceso: 16/10/2020]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/ 32186711/.